Well, I'm specialized in molecular testing in cancer patients so FMI, BRLI, CGIX, MYGN, NEO.
Personally, the main issue that this market is facing is whether these molecular testings are approved by insurance payers through CPT codes. IF it is approved, I think these companies will have a...